TEDFORD CLARK E.,PARENT JAMES B.,DUDLER THOMAS A.,SCHWAEBLE HANS-WILHELM,DEMOPULOS GREGORY A.
申请号：
NZ62406510
公开号：
NZ624065A
申请日:
2010.10.15
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
Disclosed is use of a composition comprising an amount of a MASP-2 inhibitory agent effective to selectively inhibit MASP-2 dependent complement activation in a subject suffering from, or at risk for developing a complement-mediated coagulation disorder in the manufacture of a medicament for treating a subject suffering from, or at risk for developing, a complement-mediated coagulation disorder, wherein the complement mediated disorder is secondary to at least one of: a deficiency in a complement regulatory factor, a traumatic injury, an infection, a malignancy, surgery, a transplant rejection, a transfusion reaction, an obstetric complication, a vascular aneurysm, hepatic failure, heat stroke, burn, radiation exposure, or severe toxic reaction, and wherein the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof that binds to a portion of SEQ ID NO:6 wherein the sequences are as defined in the complete specification.
